title: [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
abstract: A patient is a 35-year-old man. By a diagnosis of descending colon cancer, descending colon ablative operation and D1 lymph node dissection were performed on April 22, 2004. It was P3H0N1SE, Stage IV in perioperative findings. Abdominal CT showed peritoneal dissemination of 1.7 cm at the right under the abdominal wall wound and 1.2 cm in the rectovesical pouch on May 18, 2004. CPT-11 + TS-1 combination chemotherapy was started on June 22nd. In the five weeks of the combination chemotherapy, continuous infusion of CPT-11 (150 mg/body day 1 and 15) was twice administered, and oral administration of TS-1 (120 mg/body/day) was given for 3 weeks (day 1-21). Peritoneal dissemination disappeared after the two-course end, and we judged it as CR. Furthermore, we were certain that we obtained CR after the three course end. The adverse event was only neutropenia of grade 1. The fourth course was not administered, but recurrence has not been observed. Abdominal CT showed no recurrence on March 3, 2005 since the combination chemotherapy ended 6 months ago.
authors.affiliation: Dept. of Surgery, Sakai Municipal Hospital.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Takemoto
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Ryota
authors.initials: R
authors.lastname: Ooshiro
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujishima
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Junichi
authors.initials: J
authors.lastname: Tanaka
authors.forename: Motoi
authors.initials: M
authors.lastname: Kondo
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Seizo
authors.initials: S
authors.lastname: Masutani
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tatsuta
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003110:Colonic Neoplasms / Q000473:pathology; D004338:Drug Combinations; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008297:Male; D009366:Neoplasm Seeding; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin